171 related articles for article (PubMed ID: 38134062)
101. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
Sposito C; Cucchetti A; Mazzaferro V
Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
[TBL] [Abstract][Full Text] [Related]
102. Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study.
Cao L; Wang X; Yan Y; Ning Z; Ma L; Li Y
Medicine (Baltimore); 2023 Dec; 102(51):e36705. PubMed ID: 38134062
[TBL] [Abstract][Full Text] [Related]
103. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study.
Jepsen P; Ott P; Andersen PK; Sørensen HT; Vilstrup H
Ann Intern Med; 2012 Jun; 156(12):841-7, W295. PubMed ID: 22711076
[TBL] [Abstract][Full Text] [Related]
104. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
105. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
106. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
107. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
[TBL] [Abstract][Full Text] [Related]
108. Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome.
Afra F; Mahboobipour AA; Salehi Farid A; Ala M
Biomed Pharmacother; 2023 Sep; 165():115104. PubMed ID: 37393866
[TBL] [Abstract][Full Text] [Related]
109. Cardiovascular-Specific Mortality among Gastrointestinal Stromal Tumor Patients: A Population-Based Analysis.
Yao H; Shi H; Fan M; Yuan L; Lin R
Oxid Med Cell Longev; 2023; 2023():3619306. PubMed ID: 36825080
[TBL] [Abstract][Full Text] [Related]
110. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors.
Wang Z; Fan Z; Yang L; Liu L; Sheng C; Song F; Huang Y; Chen K
Front Cardiovasc Med; 2023; 10():1014400. PubMed ID: 36760569
[TBL] [Abstract][Full Text] [Related]
111. Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.
Antwi SO; Craver EC; Nartey YA; Sartorius K; Patel T
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551719
[TBL] [Abstract][Full Text] [Related]
112. Fatal heart disease in patients with bone and soft tissue sarcoma.
Chen B; Zhao X; Li X; Liu J; Tang J
Front Cardiovasc Med; 2022; 9():951940. PubMed ID: 36312272
[TBL] [Abstract][Full Text] [Related]
113. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
Pantazi D; Tselepis AD
Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
[TBL] [Abstract][Full Text] [Related]
114. Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors.
Fuster JJ
Thromb Res; 2022 May; 213 Suppl 1():S107-S112. PubMed ID: 36210552
[TBL] [Abstract][Full Text] [Related]
115. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Lyon AR; López-Fernández T; Couch LS; Asteggiano R; Aznar MC; Bergler-Klein J; Boriani G; Cardinale D; Cordoba R; Cosyns B; Cutter DJ; de Azambuja E; de Boer RA; Dent SF; Farmakis D; Gevaert SA; Gorog DA; Herrmann J; Lenihan D; Moslehi J; Moura B; Salinger SS; Stephens R; Suter TM; Szmit S; Tamargo J; Thavendiranathan P; Tocchetti CG; van der Meer P; van der Pal HJH;
Eur Heart J Cardiovasc Imaging; 2022 Sep; 23(10):e333-e465. PubMed ID: 36017575
[No Abstract] [Full Text] [Related]
116. Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study.
Wang S; Ge C; Zhang J
J Cardiovasc Dev Dis; 2022 Aug; 9(8):. PubMed ID: 36005419
[TBL] [Abstract][Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
